Emily Lauren Ward
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Emily Lauren Ward has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Alaa Hussien-Ali
1 shared publication- Amogh Changavi
Vision Science Graduate Group, University of California Berkeley, Berkeley, CA, United States; Herbert Wertheim School of Optometry & Vision Science, University of California Berkeley, Berkeley, CA, United States
1 shared publication - Jeremy M. Sivak
Donald K Johnson Eye Institute, University Health Network, Toronto, ON, Canada; Department of Ophthalmology and Vision Science, University of Toronto, Temerty Faculty of Medicine, Canada
1 shared publication - John G. Flanagan
Vision Science Graduate Group, University of California Berkeley, Berkeley, CA, United States; Herbert Wertheim School of Optometry & Vision Science, University of California Berkeley, Berkeley, CA, United States
1 shared publication - Karsten Gronert
Vision Science Graduate Group, University of California Berkeley
1 shared publication - Matangi Kumar
Vision Science Graduate Group, University of California Berkeley, Berkeley, CA, United States; Herbert Wertheim School of Optometry & Vision Science, University of California Berkeley, Berkeley, CA, United States
1 shared publication
Latest Publications
- Open Access
- 18 March 2026
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 112, 101460
The role of prostanoids in the retina and optic nerve in health and disease
- 18 March 2026
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 112, 101460
Open AccessThe role of prostanoids in the retina and optic nerve in health and disease
- Open Access
Jasmonic acid and methyl jasmonate attenuate neuroinflammation via crosstalk with the prostaglandin E 2 /receptor EP2 signaling axis
The jasmonates are a class of oxylipin phytohormones known to exhibit anti-inflammatory, antioxidant, and anti-cancer effects in mammalian cells. We investigated the ability of three jasmonate compounds (jasmonic acid, methyl jasmonate, and 12-OPDA) and two structurally distinct jasmonate precursors (alpha-linolenic acid and palmitic acid) to attenuate inflammation in an in vitro model of neurodegenerative disease, for which the mechanisms of action have not been well identified. The study modeled chronic neuroinflammation in SH-SY5Y neuroblastoma cells using exogenous prostaglandin E 2 (PGE 2 ) treatment. Prostaglandin E 2 caused concentration-dependent levels of inflammation and SH-SY5Y cell death, which were attenuated by the jasmonates and their precursors. To this end, structural similarities between the jasmonates and PGE 2 were correlated with increased potency of their anti-inflammatory effects. Downstream biomarkers of signaling through the pro-inflammatory E prostanoid receptor subtype 2 (EP2) were then quantified using enzyme-linked immunosorbent assay methods. Of the compounds tested, only jasmonic acid and methyl jasmonate attenuated inflammation in the SH-SY5Y cells via crosstalk with the PGE 2 /EP2 signaling axis. Additionally, structural models and molecular binding simulations serve as evidence for our hypothesis that JA and MeJA achieve this crosstalk through competitive inhibition of the receptor EP2. This novel finding has implications in the study of neurodegenerative diseases for which the disease pathology is related to chronic neuroinflammation, including Alzheimer’s Disease (AD), Parkinson’s Disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). In addition, these findings add to the understanding of the relationship between pro-inflammatory prostaglandin E 2 signaling and disease severity.
Open AccessJasmonic acid and methyl jasmonate attenuate neuroinflammation via crosstalk with the prostaglandin E 2 /receptor EP2 signaling axis
The jasmonates are a class of oxylipin phytohormones known to exhibit anti-inflammatory, antioxidant, and anti-cancer effects in mammalian cells. We investigated the ability of three jasmonate compounds (jasmonic acid, methyl jasmonate, and 12-OPDA) and two structurally distinct jasmonate precursors (alpha-linolenic acid and palmitic acid) to attenuate inflammation in an in vitro model of neurodegenerative disease, for which the mechanisms of action have not been well identified. The study modeled chronic neuroinflammation in SH-SY5Y neuroblastoma cells using exogenous prostaglandin E 2 (PGE 2 ) treatment. Prostaglandin E 2 caused concentration-dependent levels of inflammation and SH-SY5Y cell death, which were attenuated by the jasmonates and their precursors. To this end, structural similarities between the jasmonates and PGE 2 were correlated with increased potency of their anti-inflammatory effects. Downstream biomarkers of signaling through the pro-inflammatory E prostanoid receptor subtype 2 (EP2) were then quantified using enzyme-linked immunosorbent assay methods. Of the compounds tested, only jasmonic acid and methyl jasmonate attenuated inflammation in the SH-SY5Y cells via crosstalk with the PGE 2 /EP2 signaling axis. Additionally, structural models and molecular binding simulations serve as evidence for our hypothesis that JA and MeJA achieve this crosstalk through competitive inhibition of the receptor EP2. This novel finding has implications in the study of neurodegenerative diseases for which the disease pathology is related to chronic neuroinflammation, including Alzheimer’s Disease (AD), Parkinson’s Disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). In addition, these findings add to the understanding of the relationship between pro-inflammatory prostaglandin E 2 signaling and disease severity.